Concepedia

Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis

Hyungwoo Cho, Min‐Hee Ryu, Kyu‐pyo Kim, Baek‐Yeol Ryoo, Sook Ryun Park, Bum Soo Kim, In‐Seob Lee, Hee‐Sung Kim, Moon‐Won Yoo, Jeong Hwan Yook,

Gastric Cancer · 2017 · 23 citations · 22 references

DOIFull text

Open access

Concepts

References

22

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit et al. · International Journal of Cancer · 2014 · 29K citations · Full text

, , +16

Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

Eric Van Cutsem, Vladimir Moiseyenko, Sergei Tjulandin et al. · Journal of Clinical Oncology · 2006 · 1.9K citations · Full text

, , +11

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

Wasaburo Koizumi, Hiroyuki Narahara, Takuo Hara et al. · The Lancet Oncology · 2008 · 1.9K citations

, , +7

One-Sample Multiple Testing Procedure for Phase II Clinical Trials

Thomas R. Fleming · Biometrics · 1982 · 997 citations

, , +13

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

Yoon‐Koo Kang, Won Ki Kang, D.B. Shin et al. · Annals of Oncology · 2009 · 777 citations · Full text

, , +15